ClinicalTrials.gg
CompletedNCT02004691ASCENDUpdated Nov 7, 2024Results posted

Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

A Phase 2/3 interventional study of placebo (saline) and Olipudase alfa in Sphingomyelin Lipidosis, sponsored by Genzyme, a Sanofi Company. Completed at 24 sites in 17 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Primary Objective:

The primary objective of this phase 2/3 study was to evaluate the efficacy of olipudase alfa (recombinant human acid sphingomyelinase) administered intravenously once every 2 weeks for 52 weeks in adult participants with acid sphingomyelinase deficiency (ASMD) by assessing changes in: 1) spleen volume as measured by abdominal magnetic resonance imaging (MRI) (and, for the United States [US] only, in association with participant perception related to spleen volume as measured by splenomegaly-related score [SRS]); and 2) infiltrative lung disease as measured by the pulmonary function test, diffusing capacity of the lung for carbon monoxide (DLCO).

Secondary Objectives:

  • To confirm the safety of olipudase alfa administered intravenously once every 2 weeks for 52 weeks.
  • To characterize the effect of olipudase alfa on the participant perception related to spleen volume as measured by the SRS after 52 weeks of study drug administration. (For the US, the effect of olipudase alfa on the SRS is part of the primary objective).
  • To characterize the effect of olipudase alfa after 52 weeks of study drug administration on the following outcome measures assessed sequentially:

    • The effect of olipudase alfa on liver volume;
    • The effect of olipudase alfa on platelet count;
    • The effect of olipudase alfa on fatigue;
    • The effect of olipudase alfa on pain;
    • The effect of olipudase alfa on dyspnea.
Read the detailed description

The planned total duration per participant was for at least 3 years and up to 5 years and 3 months. This included up to approximately two month of screening, 52 weeks of primary analysis period, up to 4 years and 3 months of extension treatment period, an end-of- study visit within 2 weeks of the last treatment, and a safety follow-up 30 to 37 days after the last treatment.

02

Conditions studied

  • Sphingomyelin Lipidosis
03

In context

Niemann-Pick Disease, Type A

10 studies on the registry are indexed under Niemann-Pick Disease, Type A; 1 is open to participants now.

Browse Niemann-Pick Disease, Type A studies →

Lead sponsor

Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.

First submitted after Genzyme became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant was willing and able to provide signed written .
  • The participant was male or female aged 18 years or older.
  • The participant had documented deficiency of acid sphingomyelinase as measured in peripheral leukocytes, cultured fibroblasts, or lymphocytes; and a clinical diagnosis consistent with Niemann-Pick disease type B (NPD B).
  • The participant had diffuse capacity of the lung for carbon monoxide less than or equal to (\<=)70% of the predicted normal value.
  • The participant had a spleen volume greater than or equal to (>=)6 multiples of normal (MN) measured by MRI; participant who have had partial splenectomy was allowed if the procedure was performed >=1 year before screening/baseline and the residual spleen volume was >=6 MN.
  • The participant had an SRS >=5.
  • Female participants of must have had a negative serum pregnancy test for beta-human chorionic gonadotropin (β-HCG).
  • Female participants of childbearing potential and male participants were willing to practice true abstinence in line with their preferred and usual lifestyle, or use 2 acceptable effective methods of for up to 15 days following their last dose of study drug.

Exclusion criteria

Exclusion criteria:

  • The participant had received an drug within 30 days before study enrollment.
  • The participant had a medical condition, including significant intercurrent illness; significant cardiac disease (e.g., arrhythmia, moderate or severe pulmonary hypertension or clinically significant valve dysfunction, or less than or equal to (\<=)40% by echocardiogram); active or , or infection with (HIV); diagnosed within the past 5 years (other than non-melanoma skin cancer), or any other serious medical condition that might have precluded participation in the study.
  • The participant had a count less than (\<)60,000/microliters based on the average of 2 samples.
  • The participant had an (INR) greater than (>)1.5.
  • The participant had (ALT) or aspartate aminotransferase (AST) >250 IU/L or total >1.5 mg/dL (except for participant with Gilbert's syndrome).
  • The participant had a major organ transplant (eg, bone marrow or liver).
  • The participant was scheduled during the study for in-patient hospitalization including elective surgery and excluding the liver required per protocol.
  • The participant, in the opinion of the investigator, was unable to adhere to the requirements of the study.
  • The participant was unwilling or unable to abstain from the use of alcohol for 1 day before and 3 days after each study drug infusion. Testing for blood alcohol levels was not required.
  • The participant was unwilling or unable to avoid 10 days before and 3 days after the protocol scheduled liver biopsies the use of medications or herbal supplements that were potentially hepatotoxic (e.g., 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors, erythromycin, valproic acid, anti-depressants, kava, echinacea) and/or might have caused or prolonged bleeding (e.g., anti-coagulants, ibuprofen, aspirin, garlic supplements, ginkgo, ginseng).
  • The participant required medications that might have decreased olipudase alfa activity (e.g., fluoxetine, chlorpromazine, tricyclic antidepressants [e.g., imipramine, or desipramine]).
  • The participant required use of invasive ventilatory support.
  • The participant required use of noninvasive ventilator support while awake for longer than 12 hours daily.
  • The participant was breast-feeding.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo (saline) administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to placebo.

    Drug: placebo (saline)

  • Experimental
    Olipudase alfa

    Olipudase alfa dose (3 mg/kg body weight) in saline administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to olipudase alfa, and during the extension treatment period for all patients.

    Drug: Olipudase alfa

Interventions

  • Drugplacebo (saline)

    Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo. Route of administration: intravenous infusion

  • Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants. Route of administration: intravenous infusion

    Also known as: GZ402665, Xenpozyme™

06

What researchers measure

Primary outcomes

  1. Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Baseline

    Percent predicted Hb and Altitude-adjusted DLco was calculated as: 100\*Adjusted DLco/Predicted DLco in unit of mL CO/min/mmHg where, adjusted DLco = Observed DLco (in mL CO/min/mmHg) times Hemoglobin-adjusted factor times Altitude-adjustment factor.

    Time frame: Baseline (Day 1)

  2. Percent Change From Baseline in Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Week 52

    Percent predicted Hb and Altitude-adjusted DLco was calculated as: 100\*Adjusted DLco/Predicted DLco in unit of mL CO/min/mmHg where, adjusted DLco = Observed DLco (in mL CO/min/mmHg) times Hemoglobin-adjusted factor times Altitude-adjustment factor.

    Time frame: Baseline, Week 52

  3. Combination Spleen Endpoint: Component 1: Spleen Volume (in MN) at Baseline

    Spleen volume was assessed by abdominal magnetic resonance imaging (MRI) to quantitate the degree of splenomegaly in multiples of normal (MN).

    Time frame: Baseline (Day 1)

  4. Combination Spleen Endpoint: Component 1: Percent Change From Baseline in Spleen Volume (in MN) at Week 52

    Spleen volume was assessed by abdominal MRI to quantitate the degree of splenomegaly in MN.

    Time frame: Baseline, Week 52

  5. Combination Spleen Endpoint (Primary for US Only): Component 2: Splenomegaly-Related Score (SRS) at Baseline

    The SRS rates 5 items: abdominal pain, abdominal discomfort, early satiety, dissatisfaction with abdominal body image, and difficulty to bend down using a numerical rating scale of 0 (absent) to 10 (worst imaginable). The total score of SRS ranges from 0 to 50, with higher scores (50) indicated worst imaginable rating. It was pre-specified as secondary endpoint for countries outside of US.

    Time frame: Baseline (Day 1)

  6. Combination Spleen Endpoint (Primary for US Only): Component 2: Change From Baseline in Splenomegaly-Related Score (SRS) at Week 52

    The SRS rates 5 items: abdominal pain, abdominal discomfort, early satiety, dissatisfaction with abdominal body image, and difficulty to bend down using a numerical rating scale of 0 (absent) to 10 (worst imaginable). The total score of SRS ranges from 0 to 50, with higher scores (50) indicated worst imaginable rating. It was pre-specified as secondary endpoint for countries outside of US.

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) up to Week 52

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TESAEs was defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. Reported AEs are treatment-emergent AEs that developed, worsened or became serious during the treatment period.

    Time frame: From the first infusion of investigational medicinal product (IMP) up to 52 weeks

  2. Number of Participants With Adverse Events of Special Interest (AESIs) up to Week 52

    An AESI was defined as an AE (serious or nonserious) of scientific and medical concern specific to sponsor's product or program, for which ongoing monitoring and rapid communication by investigator to sponsor was appropriate. AESIs included any pregnancy, symptomatic overdose, dose-limiting toxicities (DLTs) as defined in protocol and infusion associated reactions (IARs). Protocol-defined IARs were AEs that occurred during the infusion or within up to 24 hours after the start of infusion and were considered as related or possibly related to the study treatment by the investigator or the sponsor. Events occurring greater than or equal to (\>=) 24 hours after the start of an infusion might have been judged an IAR at the discretion of the investigator or sponsor. Algorithm-defined IARs were all AEs that started between the start of infusion and the end of infusion plus 24 hours, irrespective of the perceived relation with study treatment.

    Time frame: From the first infusion of IMP up to 52 weeks

  3. Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Liver Function Tests up to Week 52

    PCSA criteria: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): \>3 x upper limit of normal (ULN), \>5 x ULN, \>10 x ULN and \>20 x ULN. Alkaline phosphatase (ALP) \> 1.5 x ULN. Total bilirubin \>1.5 x ULN and \>2 x ULN. ALT and total bilirubin: ALT \> 3 x ULN and total bilirubin \> 2 x ULN. Baseline was defined as the last non-missing value prior to the first infusion of study treatment.

    Time frame: From Baseline (Day 1) up to 52 weeks

  4. Number of Participants Who Developed Anti-Drug Antibodies (ADA) to Olipudase Alfa up to Week 52

    Number of participants with treatment-emergent ADA are presented. Baseline was defined as the last non-missing value prior to the first infusion of study treatment.

    Time frame: Baseline (Day 1) and Week 52

  5. Percent Change From Baseline in Liver Volume (in MN) at Week 52

    Liver volume was assessed by abdominal MRI in MN.

    Time frame: Baseline, Week 52

  6. Percent Change From Baseline in Platelet Counts at Week 52

    Time frame: Baseline, Week 52

  7. Change From Baseline in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI)-Item 3 Scale Score at Week 52

    The BFI is a 9-item, validated, self-administered questionnaire that was originally developed to assess fatigue severity. The 9-items were measured on a 0-10 scale, with 0 being 'does not interfere' and 10 being 'completely interferes.' BFI - Item 3 asks participants to "Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your worst level of fatigue during the past 24 hours. Numerical rating scale ranges from 0 (no fatigue) to 10 (worst imaginable fatigue). Higher global scores were associated with more severe fatigue.

    Time frame: Baseline, Week 52

  8. Change From Baseline in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score at Week 52

    The BPI-SF is a validated, self-administered questionnaire designed to measure a participant's perceived level of pain. The BPI-SF consisted of 15 items that use a numeric rating scale to assess pain severity and pain interference in the past 24 hours and the past week. For BPI-SF Item 3 asks participants to "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the past 24 hours." The numeric rating scale ranged from 0 (no pain) to 10 (worst imaginable pain), where higher scores indicate greater intensity of pain.

    Time frame: Baseline, Week 52

  9. Change From Baseline in Dyspnea Severity as Measured by Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnea Scale at Week 52

    FACIT-Dyspnea is a 20 Item assessment that is split into two 10-item sections. The first 10-item section asks participants about the severity of their shortness of breath during various activities. The second 10-item section asks participants to rate the difficulty due to shortness of breath associated with the same activities that were referenced in the first section. For the dyspnea severity items, score range from 0=no shortness of breath; 1=mildly short of breath; 2=moderately short of breath; 3=severely short of breath. For the functional limitation items, score range from no difficult = 0, A little difficult = 1, some difficult = 2, and much difficulty =3. A raw score was calculated as: sum of individual item scores \* 10/number of items answered. Raw scores were then converted to scale scores using the table included in the FACIT Dyspnea Scale Short Form Scoring Guideline. FACIT dyspnea scale score ranged between 27.7 to 75.9. Higher score represented high levels of dyspnea.

    Time frame: Baseline, Week 52

07

Results

Posted May 24, 2022

Participant flow

The study was conducted at 23 active centers in 17 countries. A total of 62 participants were screened between 18 December 2015 and 22 October 2018, out of which 36 participants were randomized.

PAP: Up to 52 Weeks
Participant flow — PAP: Up to 52 Weeks
MilestonePlaceboOlipudase Alfa
Started1818
Completed1718
Not completed10
Withdrew: Poor compliance10
ETP: From Week 52 up to 5 Years
Participant flow — ETP: From Week 52 up to 5 Years
MilestonePlaceboOlipudase Alfa
Started1718
Completed1316
Not completed42
Withdrew: Related to coronavirus disease (covid-19)10
Withdrew: Withdrawal by subject11
Withdrew: Pregnancy10
Withdrew: Adverse event not related to covid-1910
Withdrew: Not related to covid-1901

Outcome measures

PrimaryPercent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Baseline

Percent predicted Hb and Altitude-adjusted DLco was calculated as: 100\*Adjusted DLco/Predicted DLco in unit of mL CO/min/mmHg where, adjusted DLco = Observed DLco (in mL CO/min/mmHg) times Hemoglobin-adjusted factor times Altitude-adjustment factor.

Time frame:
Baseline (Day 1)
Reported as:
Mean · % Predicted DLco
Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Baseline
% Predicted DLcoPlaceboOlipudase Alfa
Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Baseline48.45 ± 10.7649.44 ± 10.99
PrimaryPercent Change From Baseline in Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Week 52

Percent predicted Hb and Altitude-adjusted DLco was calculated as: 100\*Adjusted DLco/Predicted DLco in unit of mL CO/min/mmHg where, adjusted DLco = Observed DLco (in mL CO/min/mmHg) times Hemoglobin-adjusted factor times Altitude-adjustment factor.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Week 52
percent changePlaceboOlipudase Alfa
Percent Change From Baseline in Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Week 522.961 ± 3.383221.968 ± 3.3362
Statistical analysis
  • Placebo vs Olipudase Alfa · Mixed model for repeated measures · p = =0.0004 (Threshold for significance was 0.05.) · Least squares mean difference: 19.008 · 95% CI 9.319 to 28.696The 95% Confidence Interval (CI) and p-values were based on mixed model for repeated measures approach with Baseline Derived % Predicted DLco adjusted for Hb and pressure, age, treatment group, visit, and study visit by treatment group as covariates.
PrimaryCombination Spleen Endpoint: Component 1: Spleen Volume (in MN) at Baseline

Spleen volume was assessed by abdominal magnetic resonance imaging (MRI) to quantitate the degree of splenomegaly in multiples of normal (MN).

Time frame:
Baseline (Day 1)
Reported as:
Mean · multiples of normal (MN)
Combination Spleen Endpoint: Component 1: Spleen Volume (in MN) at Baseline
multiples of normal (MN)PlaceboOlipudase Alfa
Combination Spleen Endpoint: Component 1: Spleen Volume (in MN) at Baseline11.21 ± 3.8411.69 ± 4.92
PrimaryCombination Spleen Endpoint: Component 1: Percent Change From Baseline in Spleen Volume (in MN) at Week 52

Spleen volume was assessed by abdominal MRI to quantitate the degree of splenomegaly in MN.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · percent change
Combination Spleen Endpoint: Component 1: Percent Change From Baseline in Spleen Volume (in MN) at Week 52
percent changePlaceboOlipudase Alfa
Combination Spleen Endpoint: Component 1: Percent Change From Baseline in Spleen Volume (in MN) at Week 520.481 ± 2.5002-39.446 ± 2.4294
Statistical analysis
  • Placebo vs Olipudase Alfa · Mixed model for repeated measures · p = <.0001 (Threshold for significance was 0.05.) · Least squares mean difference: -39.927 · 95% CI -47.051 to -32.803The 95% CI and p-values were based on a mixed model for repeated measures approach with Baseline Spleen Volume (MN), Baseline age, treatment group, study visit, and study visit by treatment group interaction as covariates.
PrimaryCombination Spleen Endpoint (Primary for US Only): Component 2: Splenomegaly-Related Score (SRS) at Baseline

The SRS rates 5 items: abdominal pain, abdominal discomfort, early satiety, dissatisfaction with abdominal body image, and difficulty to bend down using a numerical rating scale of 0 (absent) to 10 (worst imaginable). The total score of SRS ranges from 0 to 50, with higher scores (50) indicated worst imaginable rating. It was pre-specified as secondary endpoint for countries outside of US.

Time frame:
Baseline (Day 1)
Reported as:
Mean · score on a scale
Combination Spleen Endpoint (Primary for US Only): Component 2: Splenomegaly-Related Score (SRS) at Baseline
score on a scalePlaceboOlipudase Alfa
Combination Spleen Endpoint (Primary for US Only): Component 2: Splenomegaly-Related Score (SRS) at Baseline28.05 ± 10.5624.55 ± 11.13
PrimaryCombination Spleen Endpoint (Primary for US Only): Component 2: Change From Baseline in Splenomegaly-Related Score (SRS) at Week 52

The SRS rates 5 items: abdominal pain, abdominal discomfort, early satiety, dissatisfaction with abdominal body image, and difficulty to bend down using a numerical rating scale of 0 (absent) to 10 (worst imaginable). The total score of SRS ranges from 0 to 50, with higher scores (50) indicated worst imaginable rating. It was pre-specified as secondary endpoint for countries outside of US.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Combination Spleen Endpoint (Primary for US Only): Component 2: Change From Baseline in Splenomegaly-Related Score (SRS) at Week 52
score on a scalePlaceboOlipudase Alfa
Combination Spleen Endpoint (Primary for US Only): Component 2: Change From Baseline in Splenomegaly-Related Score (SRS) at Week 52-9.281 ± 2.4165-7.664 ± 2.3481
Statistical analysis
  • Placebo vs Olipudase Alfa · Mixed model for repeated measures · p = =0.6364 (Threshold for significance was 0.15.) · Least squares mean difference: 1.618 · 95% CI -5.302 to 8.538The 95% CI and p-values are based on a mixed model for repeated measures approach with Baseline Splenomegaly Related Score, Baseline age, treatment group, study visit, and study visit by treatment group interaction as covariates.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) up to Week 52

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TESAEs was defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. Reported AEs are treatment-emergent AEs that developed, worsened or became serious during the treatment period.

Time frame:
From the first infusion of investigational medicinal product (IMP) up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) up to Week 52
ParticipantsPlaceboOlipudase Alfa
TEAEs1818
TESAEs43
SecondaryNumber of Participants With Adverse Events of Special Interest (AESIs) up to Week 52

An AESI was defined as an AE (serious or nonserious) of scientific and medical concern specific to sponsor's product or program, for which ongoing monitoring and rapid communication by investigator to sponsor was appropriate. AESIs included any pregnancy, symptomatic overdose, dose-limiting toxicities (DLTs) as defined in protocol and infusion associated reactions (IARs). Protocol-defined IARs were AEs that occurred during the infusion or within up to 24 hours after the start of infusion and were considered as related or possibly related to the study treatment by the investigator or the sponsor. Events occurring greater than or equal to (\>=) 24 hours after the start of an infusion might have been judged an IAR at the discretion of the investigator or sponsor. Algorithm-defined IARs were all AEs that started between the start of infusion and the end of infusion plus 24 hours, irrespective of the perceived relation with study treatment.

Time frame:
From the first infusion of IMP up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs) up to Week 52
ParticipantsPlaceboOlipudase Alfa
Pregnancy00
Symptomatic Overdose00
DLTs51
Protocol-defined IARs58
Algorithm-defined IARs1315
SecondaryNumber of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Liver Function Tests up to Week 52

PCSA criteria: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): \>3 x upper limit of normal (ULN), \>5 x ULN, \>10 x ULN and \>20 x ULN. Alkaline phosphatase (ALP) \> 1.5 x ULN. Total bilirubin \>1.5 x ULN and \>2 x ULN. ALT and total bilirubin: ALT \> 3 x ULN and total bilirubin \> 2 x ULN. Baseline was defined as the last non-missing value prior to the first infusion of study treatment.

Time frame:
From Baseline (Day 1) up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Liver Function Tests up to Week 52
ParticipantsPlaceboOlipudase Alfa
ALT: >3 x ULN21
ALT: >5 x ULN11
ALT: >10 x ULN00
ALT: >20 x ULN00
AST: >3 x ULN22
AST: >5 x ULN11
AST: >10 x ULN00
AST: >20 x ULN00
ALP: >1.5 x ULN11
Total Bilirubin: >1.5 x ULN44
Total Bilirubin: >2 x ULN14
ALT >3 x ULN and total bilirubin >2 x ULN01
SecondaryNumber of Participants Who Developed Anti-Drug Antibodies (ADA) to Olipudase Alfa up to Week 52

Number of participants with treatment-emergent ADA are presented. Baseline was defined as the last non-missing value prior to the first infusion of study treatment.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-Drug Antibodies (ADA) to Olipudase Alfa up to Week 52
ParticipantsPlaceboOlipudase Alfa
Number of Participants Who Developed Anti-Drug Antibodies (ADA) to Olipudase Alfa up to Week 5214
SecondaryPercent Change From Baseline in Liver Volume (in MN) at Week 52

Liver volume was assessed by abdominal MRI in MN.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Liver Volume (in MN) at Week 52
percent changePlaceboOlipudase Alfa
Percent Change From Baseline in Liver Volume (in MN) at Week 52-1.468 ± 2.5409-28.064 ± 2.4899
Statistical analysis
  • Placebo vs Olipudase Alfa · Mixed model for repeated measures · p = <.0001 (Threshold for significance was 0.05.) · Least squares mean difference: -26.596 · 95% CI -33.911 to -19.281The 95% CI and p-values are based on a mixed model for repeated measures approach with Baseline Liver Volume (MN), Baseline age, treatment group, study visit, and study visit by treatment group interaction as covariates.
SecondaryPercent Change From Baseline in Platelet Counts at Week 52
Time frame:
Baseline, Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Platelet Counts at Week 52
percent changePlaceboOlipudase Alfa
Percent Change From Baseline in Platelet Counts at Week 522.490 ± 4.192316.822 ± 3.9596
Statistical analysis
  • Placebo vs Olipudase Alfa · Mixed model for repeated measures · p = =0.0185 (Threshold for significance was 0.05.) · Least squares mean difference: 14.332 · 95% CI 2.564 to 26.099The 95% CI and p-values are based on a mixed model for repeated measures approach with Baseline Platelets, Baseline age, treatment group, study visit, and study visit by treatment group interaction as covariates.
SecondaryChange From Baseline in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI)-Item 3 Scale Score at Week 52

The BFI is a 9-item, validated, self-administered questionnaire that was originally developed to assess fatigue severity. The 9-items were measured on a 0-10 scale, with 0 being 'does not interfere' and 10 being 'completely interferes.' BFI - Item 3 asks participants to "Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your worst level of fatigue during the past 24 hours. Numerical rating scale ranges from 0 (no fatigue) to 10 (worst imaginable fatigue). Higher global scores were associated with more severe fatigue.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI)-Item 3 Scale Score at Week 52
score on a scalePlaceboOlipudase Alfa
Change From Baseline in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI)-Item 3 Scale Score at Week 52-1.806 ± 0.5272-1.862 ± 0.5129
Statistical analysis
  • Placebo vs Olipudase Alfa · Mixed model for repeated measures · p = =0.9400 (Threshold for significance was 0.05.) · Least squares mean difference: -0.056 · 95% CI -1.566 to 1.454The 95% CI and p-values are based on a mixed model for repeated measures approach with Baseline BFI item 3 (Worst Fatigue), Baseline age, treatment group, study visit, and study visit by treatment group interaction as covariates.
SecondaryChange From Baseline in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score at Week 52

The BPI-SF is a validated, self-administered questionnaire designed to measure a participant's perceived level of pain. The BPI-SF consisted of 15 items that use a numeric rating scale to assess pain severity and pain interference in the past 24 hours and the past week. For BPI-SF Item 3 asks participants to "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the past 24 hours." The numeric rating scale ranged from 0 (no pain) to 10 (worst imaginable pain), where higher scores indicate greater intensity of pain.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score at Week 52
score on a scalePlaceboOlipudase Alfa
Change From Baseline in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score at Week 52-2.293 ± 0.5899-1.404 ± 0.5742
SecondaryChange From Baseline in Dyspnea Severity as Measured by Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnea Scale at Week 52

FACIT-Dyspnea is a 20 Item assessment that is split into two 10-item sections. The first 10-item section asks participants about the severity of their shortness of breath during various activities. The second 10-item section asks participants to rate the difficulty due to shortness of breath associated with the same activities that were referenced in the first section. For the dyspnea severity items, score range from 0=no shortness of breath; 1=mildly short of breath; 2=moderately short of breath; 3=severely short of breath. For the functional limitation items, score range from no difficult = 0, A little difficult = 1, some difficult = 2, and much difficulty =3. A raw score was calculated as: sum of individual item scores \* 10/number of items answered. Raw scores were then converted to scale scores using the table included in the FACIT Dyspnea Scale Short Form Scoring Guideline. FACIT dyspnea scale score ranged between 27.7 to 75.9. Higher score represented high levels of dyspnea.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Dyspnea Severity as Measured by Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnea Scale at Week 52
score on a scalePlaceboOlipudase Alfa
Change From Baseline in Dyspnea Severity as Measured by Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnea Scale at Week 52-6.769 ± 1.9132-5.862 ± 1.6918

Adverse events

Collected over For PAP: From the first infusion of IMP up to 52 weeks. For ETP: From Week 52 up to 5 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PAP: Placebo0/18 (0%)4/18 (22.2%)13/18 (72.2%)
PAP: Olipudase Alfa0/18 (0%)3/18 (16.7%)17/18 (94.4%)
ETP: Placebo/Olipudase Alfa0/17 (0%)6/17 (35.3%)9/17 (52.9%)
ETP: Olipudase Alfa/Olipudase Alfa0/18 (0%)5/18 (27.8%)12/18 (66.7%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventPAP: PlaceboPAP: Olipudase AlfaETP: Placebo/Olipudase AlfaETP: Olipudase Alfa/Olipudase Alfa
Loss Of ConsciousnessNervous system disorders0/180/182/170/18
Angina PectorisCardiac disorders0/180/181/170/18
ExtrasystolesCardiac disorders0/180/181/170/18
Inguinal HerniaGastrointestinal disorders0/180/181/170/18
Non-Cardiac Chest PainGeneral disorders0/180/181/170/18
PyrexiaGeneral disorders0/180/181/170/18
Urinary Tract InfectionInfections and infestations0/180/181/170/18
Hepatocellular CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/180/181/170/18
SyncopeNervous system disorders1/180/181/170/18
PneumothoraxRespiratory, thoracic and mediastinal disorders0/180/181/170/18
Most frequent other events
Most frequent other events
EventPAP: PlaceboPAP: Olipudase AlfaETP: Placebo/Olipudase AlfaETP: Olipudase Alfa/Olipudase Alfa
HeadacheNervous system disorders8/1812/184/175/18
Covid-19Infections and infestations0/180/187/178/18
NasopharyngitisInfections and infestations6/188/185/177/18
Upper Respiratory Tract InfectionInfections and infestations4/186/183/173/18
CoughRespiratory, thoracic and mediastinal disorders2/185/181/173/18
ArthralgiaMusculoskeletal and connective tissue disorders3/184/183/171/18

Baseline characteristics

Analysis was performed on modified intent-to-treat (mITT) population which included all randomized participants who had received at least 1 infusion (partial or total) and were analyzed according to the treatment arm allocated by randomization.

Age, Continuous
Age, Continuous(years)PlaceboOlipudase AlfaTotal Title
Mean33.46 ± 17.0636.17 ± 12.7234.81 ± 14.89
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOlipudase AlfaTotal Title
Female13922
Male5914
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboOlipudase AlfaTotal Title
American Indian or Alaska Native000
Asian112
Black or African American000
Native Hawaiian or Other Pacific Islander000
White161632
More than one race000
Unknown or Not Reported000
Other112
08

Study locations

24 sites
  • UCSF Medical Center Site Number : 840005
    San Francisco, California 94143, United States
  • Emory University Site Number : 840003
    Decatur, Georgia 30033, United States
  • Montefiore Medical Center Site Number : 840006
    Bronx, New York 10467, United States
  • Investigational Site Number : 032001
    Córdoba, X5004FHP, Argentina
  • Investigational Site Number : 036001
    Westmead, New South Wales 2145, Australia
  • Investigational Site Number : 056001
    Leuven, 3000, Belgium
  • Hospital De Clinicas De Porto Alegre Site Number : 076001
    Porto Alegre, Rio Grande Do Sul 90035 003, Brazil
  • Investigational Site Number : 100001
    Sofia, 1431, Bulgaria
  • Investigational Site Number : 152001
    Santiago, Reg Metropolitana De Santiago 753-0204, Chile
  • Investigational Site Number : 250001
    Paris, 75020, France
  • Investigational Site Number : 276001
    Mainz, 55131, Germany
  • Investigational Site Number : 380002
    Napoli, 80131, Italy
  • Investigational Site Number : 380001
    Udine, 33100, Italy
  • Investigational Site Number : 392001
    Fukushima-shi, Fukushima 960-1295, Japan
  • Investigational Site Number : 528001
    Amsterdam, 1105 AZ, Netherlands
  • Investigational Site Number : 620002
    Porto, 4099-001, Portugal
  • Investigational Site Number : 724001
    Madrid, 28034, Spain
  • Investigational Site Number : 788001
    Tunis, 1007, Tunisia
  • Investigational Site Number : 792002
    Ankara, 06500, Turkey
  • Investigational Site Number : 792004
    Istanbul, 34520, Turkey
  • Investigational Site Number : 792003
    Istanbul, 34722, Turkey
  • Investigational Site Number : 792001
    Izmir, 35040, Turkey
  • Investigational Site Number : 826001
    London, London, City Of WC1N 3JZ, United Kingdom
  • Investigational Site Number : 826002
    Birmingham, B15 2GW, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Mar 2021, 62 months.

Results were first posted in May 2022, 1 year 2 months after primary completion. A results delay was requested in Oct 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2013
First posted
Dec 9, 2013
StartActual
Dec 18, 2015
Primary completionActual
Mar 15, 2021
CompletionActual
Oct 19, 2023
Results delay requested
Oct 13, 2020
Results first posted
May 24, 2022
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02004691
Responsible party
Sponsor
First posted
Dec 9, 2013
Start date
Dec 18, 2015
Primary completion
Mar 15, 2021
Completion
Oct 19, 2023
Results posted
May 24, 2022
Last update
Nov 7, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olipudase alfa

Start the discussion